Back to Careers

Ashil Koranne presented a poster at the 2024 MDA Clinical & Scientific Conference highlighting Juvena Therapeutics’ promising preclinical development of JUV-161, a novel fusion protein for treating Myotonic Dystrophy Type 1.

Back to Careers

Juvena recognized by The Wall Street Journal for developing regenerative therapies aimed at weight loss and prevention of muscle wasting

Back to Careers

Juvena gets FDA Orphan Drug nod for muscle regeneration therapy

Back to Careers

Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1

Back to Careers

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1

Back to Careers

Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”

Back to Careers

CEO Dr. Yousef speaks about “The Science of Longevity: Stopping Aging at the Cellular Level to Prevent Disease and Improve Quality of Life” as an invited panelist for the 2023 Biotech Showcase.

Back to Careers

Juvena’s CEO, Dr. Hanadie Yousef is recognized by FierceBiotech in their 2023 shortlist of 10 of the fiercest women in life sciences.

juvena-logo-wht

Navigation

Contact

640 Galveston Drive
Redwood City, CA 94063
Get Directions »
650.223.5879
info@juvenatherapeutics.com

Stay in touch

Subscribe to our newsletter

By entering your email you agree to our Privacy Policy

© 2023 Juvena Therapeutics Inc. All Rights Reserved | Privacy Policy